MedPath

Objective Brain Function Assessment of mTBI/Concussion

Completed
Conditions
Concussion, Mild
Concussion, Brain
Concussion, Intermediate
Concussion, Severe
Brain Injuries, Traumatic
Registration Number
NCT03963804
Lead Sponsor
BrainScope Company, Inc.
Brief Summary

This study (Part 3) is designed to build a database including EEG, neurocognitive performance, clinical symptoms, history and other relevant data, which will be used to derive a multimodal EEG based algorithm for the identification of concussion and tracking of recovery.

Detailed Description

Injured/concussed subjects will be studied at time of injury, and at 3 follow-up time points following injury. Subjects will come from the sports and other populations of concussed individuals. They will be matched with controls i.e. not head injured subjects who will also undergo the same set of tests and the same time intervals as the injured subjects. An additional pool of uninjured (not head injured) subjects will be collected who will be assessed at a single time point. This data will be used to populate a database for the purpose of deriving a multimodal concussion index.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
268
Inclusion Criteria

For Injured subjects:

  1. Having sustained a traumatic closed head injury within 72 hours (3 days) from time of injury at time of BrainScope assessment;
  2. GCS 13-15 at time of BrainScope assessment;
  3. No hospital admission due to either head injury or collateral injuries for >24 hours.

For Matched Controls:

  1. GCS 15 at time of BrainScope assessment;
  2. No prior history of concussion or TBI in the last year.
Exclusion Criteria
  1. Previously enrolled in the BrainScope CAS Studies;
  2. Current CNS active prescription medications taken daily, with the exception of medications being taken for the treatment of Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD);
  3. Forehead, scalp or skull abnormalities that prevents headset application or EEG data collection;
  4. History of brain surgery or neurological disease;
  5. Pregnant women;
  6. Subjects who do not speak English (non-English speaking parents are allowed to consent so long as translation of the consent form in their native language is available);
  7. Acute intoxication;
  8. Evidence of illicit drug usage;

For Injured subjects:

  1. Loss of consciousness ≥ 20 minutes related to the concussion injury;
  2. Active fever defined as greater than 100ºF or 37.78ºC at time of BrainScope assessment;
  3. Evidence of abnormality visible on Computerized Tomography (CT) of the head related to the traumatic event (Note: neuroimaging is not required for enrollment).

For Matched Controls:

  1. Any focal neurological signs including aphasia, apraxia, diplopia, facial droop, dysarthria/slurred speech;
  2. History of Motor Vehicle Accident (MVA) requiring an Emergency Department visit within the past 1 year.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Derivation of algorithm for Likelihood of being concussed using multimodal inputs6 months for data acquisition, with each patient studied from time of injury to 45 days after RTP

Create a database of all assessments including brain electrical activity (EEG features including all frequency bands and measures (power, connectivity,complexity), neurocognitive performance tests scores (throughput measures), balance, and clinical/symptom assessments (SCAT5), to support derivation of a multimodal brain function/concussion index. (NOTE: All EEG and Neurocognitive features are expressed as z-scores relative to age expected normal values to enable combination)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

University of Arkansas

🇺🇸

Fayetteville, Arkansas, United States

University of Miami

🇺🇸

Miami, Florida, United States

Michigan State University

🇺🇸

East Lansing, Michigan, United States

University of Rochester

🇺🇸

Rochester, New York, United States

University of Arkansas
🇺🇸Fayetteville, Arkansas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.